Skip to main content
PYC THERAPEUTICS LIMITED logo

PYC THERAPEUTICS LIMITED — Investor Relations & Filings

Ticker · PYC ISIN · AU000000PYC7 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,297 across all filing types
Latest filing 2012-01-04 Director's Dealing
Country AU Australia
Listing ASX PYC

About PYC THERAPEUTICS LIMITED

https://pyctx.com/

PYC Therapeutics Limited is a clinical-stage company focused on developing precision medicines for patients with rare genetic diseases. The company utilizes a proprietary drug delivery platform that combines naturally derived cell-penetrating peptides with antisense oligonucleotides to create RNA-based therapeutics. This platform is designed to overcome the challenges of delivering large therapeutic molecules into target cells, particularly within the eye and central nervous system. PYC's primary pipeline includes VP-001, a candidate for Retinitis Pigmentosa type 11, and PYC-001, targeting Autosomal Dominant Optic Atrophy. Additionally, the company is advancing programs for Polycystic Kidney Disease. By leveraging its delivery technology, PYC aims to address the underlying genetic causes of diseases that currently lack effective treatment options.

Recent filings

Filing Released Lang Actions
Change of Director`s Interest Notice 2 pages 135.3KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rules and the Corporations Act. It details changes in securities holdings by a company director, including the number of shares held before and after the change, nature of the interest, and transaction details. This matches the definition of a Director's Dealing report, which reports personal share transactions by company directors and executives (insider trades). The document is not an annual report, earnings release, or any other financial report type, but specifically a notice of director's share transactions.
2012-01-04 English
Technology Licence to Janssen Biotech 2 pages 26.7KB
Regulatory Filings Classification · 95% confidence The document is a company announcement about a licensing agreement between Phylogica Ltd and Janssen Biotech, Inc. It describes the terms of the collaboration and potential future payments but does not contain any financial statements, regulatory filings, or detailed financial data. The document is relatively short (3990 characters) and serves as a news release or update rather than a formal financial or regulatory report. There is no indication that this is an earnings release, annual report, or any other formal filing type. It is an announcement of a business collaboration and licensing deal, which fits best under the category of a general regulatory announcement or miscellaneous filing that does not fit other categories.
2012-01-02 English
Shareholder Update 2 pages 26.3KB
Capital/Financing Update Classification · 85% confidence The document is a shareholder update from Phylogica Ltd dated January 3, 2012. It discusses recent partnership agreements, financial updates including revenue and capital raised, and outlook for the company. The document is relatively short (3915 characters) and reads like a corporate announcement or update rather than a full financial report. It does not contain detailed financial statements or comprehensive analysis typical of an Annual Report (10-K) or Interim Report (IR). It also does not fit categories like Earnings Release (ER) which are usually focused on quarterly results highlights, nor is it a regulatory filing or certification. The content focuses on business progress, partnerships, and financial guidance, which aligns best with a Capital/Financing Update (CAP) due to the mention of a recent share placement raising new capital and financial guidance. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2012-01-02 English
Appendix 3B 8 pages 420.6KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 3B New issue announcement' and contains detailed information about the issuance of new securities, including the number and class of securities issued, terms of the securities, issue price, purpose of the issue, and application for quotation on the ASX. It includes sections on the quotation agreement, warranties to ASX, and lists of top holders and spread of securities. This type of document is a formal announcement related to new share issues and capital changes, consistent with regulatory filings for capital raising and securities issuance. It is not a full financial report, earnings release, or management discussion, but specifically an announcement of new securities issuance and quotation application. Therefore, the appropriate classification is 'Share Issue/Capital Change' (SHA). The document length and detail confirm it is not a mere announcement of a report but a substantive filing about capital changes.
2011-12-20 English
Notice Under Section 708A 1 page 27.4KB
Capital/Financing Update Classification · 95% confidence The document is a notice under section 708A(5) of the Corporations Act regarding the issue of ordinary shares and options by Phylogica Limited. It confirms compliance with relevant provisions and provides information about the share issue without disclosure under Part 6D.2 of the Corporations Act. The content focuses on a capital raising event and the legal notice of share issuance rather than financial results, management changes, or other report types. The document length is short (1900 characters) and is a formal announcement of a capital transaction. Therefore, it fits best under Capital/Financing Update (CAP).
2011-12-20 English
Ceasing to be a substantial holder 1 page 96.2KB
Major Shareholding Notification Classification · 100% confidence The document is a Form 605 under the Corporations Act 2001, titled 'Notice of ceasing to be a substantial holder.' It details changes in substantial shareholding, including dates, nature of changes (sale of shares), and voting interests. This type of filing is a notification of changes in significant share ownership levels, which aligns with the definition of Major Shareholding Notification (MRQ). The document is short and specific to shareholding changes, not a full financial report or other types of filings.
2011-12-15 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.